202 related articles for article (PubMed ID: 34407360)
1. Balancing the CAR T: perspectives on efficacy and safety of CAR T-cell therapy in hematologic malignancies.
Buie LW
Am J Manag Care; 2021 Aug; 27(13 Suppl):S243-S252. PubMed ID: 34407360
[TBL] [Abstract][Full Text] [Related]
2. Leukapheresis for CAR-T cell production and therapy.
Pessach I; Nagler A
Transfus Apher Sci; 2023 Dec; 62(6):103828. PubMed ID: 37838564
[TBL] [Abstract][Full Text] [Related]
3. Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies.
Yang Z; Wang Y
Chin Med J (Engl); 2023 Oct; 136(19):2285-2296. PubMed ID: 37358555
[TBL] [Abstract][Full Text] [Related]
4. Progress and Pitfalls of Chimeric Antigen Receptor T Cell Immunotherapy against T Cell Malignancies.
Angelos MG; Patel RP; Ruella M; Barta SK
Transplant Cell Ther; 2024 Feb; 30(2):171-186. PubMed ID: 37866783
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies.
Ruella M; Korell F; Porazzi P; Maus MV
Nat Rev Drug Discov; 2023 Dec; 22(12):976-995. PubMed ID: 37907724
[TBL] [Abstract][Full Text] [Related]
6. CAR-T cell therapy in hematological malignancies: Where are we now and where are we heading for?
Khan AN; Asija S; Pendhari J; Purwar R
Eur J Haematol; 2024 Jan; 112(1):6-18. PubMed ID: 37545253
[TBL] [Abstract][Full Text] [Related]
7. Infectious complications of chimeric antigen receptor (CAR) T-cell therapies.
Gea-Banacloche JC
Semin Hematol; 2023 Jan; 60(1):52-58. PubMed ID: 37080711
[TBL] [Abstract][Full Text] [Related]
8. [DESCAR-T, a nationwide registry for patient treated by CAR-T Cells in France].
Broussais F; Bay JO; Boissel N; Baruchel A; Arnulf B; Morschhauser F; Robin M; Guepin GR; Moreau P; Gandemer V; Manier S; Leguay T; Nguyen Quoc S; Schwartzmann A; Houot R; Le Gouill S
Bull Cancer; 2021 Oct; 108(10S):S143-S154. PubMed ID: 34920797
[TBL] [Abstract][Full Text] [Related]
9. Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies: A Practical Review.
Strati P; Gregory T; Majhail NS; Jain N
JCO Oncol Pract; 2023 Sep; 19(9):706-713. PubMed ID: 37406255
[TBL] [Abstract][Full Text] [Related]
10. Improving CAR T cell therapy by optimizing critical quality attributes.
Reddy OL; Stroncek DF; Panch SR
Semin Hematol; 2020 Apr; 57(2):33-38. PubMed ID: 32892841
[TBL] [Abstract][Full Text] [Related]
11. A Bright Horizon: Immunotherapy for Pediatric T-Cell Malignancies.
Newman H; Teachey DT
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955734
[TBL] [Abstract][Full Text] [Related]
12. Bibliometric analysis of research trends and active research areas in chimeric antigen receptor T cell therapy for hematologic malignancies.
Zhang G; Deng L; Lu H; Zhang W
Int J Clin Pharm; 2024 Feb; 46(1):186-194. PubMed ID: 38087131
[TBL] [Abstract][Full Text] [Related]
13. Revolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy.
Dabas P; Danda A
Med Oncol; 2023 Aug; 40(9):275. PubMed ID: 37608202
[TBL] [Abstract][Full Text] [Related]
14. Combined or Sequential Treatment with Immune Checkpoint Inhibitors and Car-T Cell Therapies for the Management of Haematological Malignancies: A Systematic Review.
Pérez-Moreno MA; Ciudad-Gutiérrez P; Jaramillo-Ruiz D; Reguera-Ortega JL; Abdel-Kader Martín L; Flores-Moreno S
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834228
[TBL] [Abstract][Full Text] [Related]
15. Toxicities, intensive care management, and outcome of chimeric antigen receptor T cells in adults: an update.
Bellal M; Malherbe J; Damaj G; Du Cheyron D
Crit Care; 2024 Mar; 28(1):69. PubMed ID: 38444031
[TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor T-cell therapies: Optimising the dose.
Dasyam N; George P; Weinkove R
Br J Clin Pharmacol; 2020 Sep; 86(9):1678-1689. PubMed ID: 32175617
[TBL] [Abstract][Full Text] [Related]
17. CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies.
Hu Y; Li J; Ni F; Yang Z; Gui X; Bao Z; Zhao H; Wei G; Wang Y; Zhang M; Hong R; Wang L; Wu W; Mohty M; Nagler A; Chang AH; van den Brink MRM; Li MD; Huang H
Nat Commun; 2022 Sep; 13(1):5313. PubMed ID: 36085303
[TBL] [Abstract][Full Text] [Related]
18. Early predictive factors of failure in autologous CAR T-cell manufacturing and/or efficacy in hematologic malignancies.
Baguet C; Larghero J; Mebarki M
Blood Adv; 2024 Jan; 8(2):337-342. PubMed ID: 38052048
[TBL] [Abstract][Full Text] [Related]
19. Cellular therapies in older adults with hematological malignancies: A case-based, state-of-the-art review.
Neuendorff NR; Khan A; Ullrich F; Yates S; Devarakonda S; Lin RJ; von Tresckow B; Cordoba R; Artz A; Rosko AE
J Geriatr Oncol; 2024 Apr; 15(3):101734. PubMed ID: 38430810
[TBL] [Abstract][Full Text] [Related]
20. [CHIMERIC ANTIGEN RECEPTOR T CELLS (CAR-T CELLS) THERAPY FOR B-CELL HEMATOLOGICAL MALIGNANCIES - FROM THE ISRAELI SOCIETY OF HEMATOLOGY AND TRANSFUSION MEDICINE].
Greenbaum U; Yehudai-Ofir D; Beyar Katz O; Shargian L; Jacoby E; Grisaru S; Zuckerman T; Ram R; Avigdor A
Harefuah; 2024 Apr; 163(4):236-243. PubMed ID: 38616634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
